FDA is committed to encouraging innovation and competition for biologics and facilitating the development of safe and effective biosimilars.
Similar Posts
FDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities
FDA and Syapse presented Real-World Data at the American Association of Clinical Research (AACR) COVID-19 and Cancer meeting. Findings from study reveal higher risk of hospitalization and death among cancer patients with COVID-19.What’s New in Regulatory Science
A newsletter on regulatory science for CDER’s stakeholdersCefiderocol Injection
Cefiderocol Injection – FDA Identified Interpretive CriteriaMaster Pharmaceuticals Group – 715800 – 09/09/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetUPDATE – Sandoz Inc. Issues Voluntary Nationwide Recall Expansion of One Additional Lot of Cefazolin for Injection Due to Product Mislabeling
Sandoz, Inc. (“Sandoz”) is initiating a voluntary nationwide recall expansion of one additional lot of Cefazolin for Injection, USP, 1 gram per vial. The lot is being recalled due to a customer complaint indicating that four (4) vials incorrectly labelled as Penicillin G Potassium for Injection, USPDermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination
DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to microbial contamination identified as Burkholderia cepecia.